- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03131011
Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos (SPOT)
Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos for Localization of Adjuvant Radiotherapy Fields in Breast Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Breast cancer patients ages 18-60 who are planned for adjuvant radiotherapy and who meet all inclusion/exclusion criteria will be offered voluntary participation in this trial. Recruitment will be open for approximately 18 months; it is anticipated that 1-2 patients will be recruited per week until the planned sample size is met. Participants will be stratified into three groups depending on their self-reported baseline Body-image satisfaction (BIS) score and will then be randomly allocated to receive conventional dark ink or UV fluorescent tattoos using permutated block randomization (4 patients per block) to ensure balance of BIS baseline average between study arms.
The investigators focus is to improve the current tattooing technique for breast cancer patients by introducing an alternate method that takes the patient's psychological perceptions of tattooing into account while first and foremost, continuing to guarantee that the current standard of accuracy in treatment delivery is maintained or improved. The investigators goal of decreasing the psychological effect of permanent radiotherapy tattoos aligns with CancerCare Manitoba's mission to improve the outcomes and quality of life for Manitobans with cancer.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female age 18-60.
- Histologically confirmed early stage invasive ductal or lobular carcinoma of a single breast (T1N0M0-T2N0M0) or DCIS/LCIS (TisNxMx or TisN0M0) of a single breast.
- Deemed fit to undergo adjuvant radiotherapy to their breast by their supervising radiation oncologist.
- Able to provide written informed consent.
- Must be willing to be contacted by e-mail and have a valid e-mail account to complete follow up self-reported body image scale questionnaires.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Intact skin at site of standard radiotherapy tattoos. Must have access to a computer and be able and willing to comply with requirements of the protocol.
Exclusion Criteria:
- History of any prior radiotherapy courses to the chest or abdomen.
- Metastatic disease.
- Node positive breast cancer.
- Bilateral breast cancer or bilateral DCIS/LCIS.
- Deep-inspiration breath hold radiotherapy technique.
- Unable or unwilling to comply with the requirements of the protocol as assessed by the study investigator or coordinator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 - UV ink
Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
|
The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light.
Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy "dot" tattoos.
Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up.
|
No Intervention: Arm 2 - Black ink
Radiotherapy tattoos will be applied using standard black ink.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body-image scale score
Time Frame: Day 0, Week 3, Week 12
|
Mean BIS scores at each time point will be calculated along with standard deviation and will be compared using the student t-test.
|
Day 0, Week 3, Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Set-up Accuracy
Time Frame: Radiation Treatment week 1 (fractions 1, 2, 3) and Treatment week 2 (one fraction)
|
Set-up accuracy will be assessed using orthogonal image sets from fractions 1, 2, 3 & one day treatment week 2 for each participant.
Pre-imaging couch angle, vertical, longitudinal and lateral positions will be compared to the post-imaging values and evaluated based on our departmental couch adjustment tolerances for image-guided radiation therapy.
|
Radiation Treatment week 1 (fractions 1, 2, 3) and Treatment week 2 (one fraction)
|
Resource Requirements (Tattooing procedure length)
Time Frame: Day 0 Simulation appointment, Radiation Treatment week 1 (fractions 1, 2, 3) and Treatment week 2 (one fraction)
|
The average time(Min) it takes to complete the tattooing procedure during simulation will be collected and compared between the two arms.
|
Day 0 Simulation appointment, Radiation Treatment week 1 (fractions 1, 2, 3) and Treatment week 2 (one fraction)
|
Resource Requirements (Treatment set-up procedure length)
Time Frame: Day 0 Simulation appointment, Radiation Treatment week 1 (fractions 1, 2, 3) and Treatment week 2 (one fraction)
|
The average time(Min) it takes to complete daily treatment set-up will be collected and compared between the two arms.
|
Day 0 Simulation appointment, Radiation Treatment week 1 (fractions 1, 2, 3) and Treatment week 2 (one fraction)
|
Radiation Therapist Evaluation Survey of UV Tattoo Method
Time Frame: Week 13
|
Clinical practicability will be evaluated qualitatively through feedback from radiation therapists through a survey measuring their satisfaction with the UV tattooing method.
|
Week 13
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julian Kim, MD, MSc, CancerCare Manitoba
- Principal Investigator: Erin V Toews, B.Sc., RTT, CancerCare Manitoba
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RRIC 2017-011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Image Disturbance
-
University of SheffieldCompletedBody Image Disturbance | Body Image | ShameUnited Kingdom
-
Southern Illinois University EdwardsvilleTerminatedBody Image DisturbanceUnited States
-
Norwegian School of Sport SciencesUniversity of Agder; Ostfold University College; University College of Southeast...CompletedQuality of Life | Physical Activity | Dietary Habits | Body Image Disturbance | Body ImageNorway
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); The Fenway InstituteUnknownMedication Adherence | Body Image DisturbanceUnited States
-
York UniversityRecruitingBody Image Disturbance | Body Dysmorphic DisorderCanada
-
Medical University of South CarolinaNational Cancer Institute (NCI)RecruitingHead and Neck Cancer | Body Image Disturbance | Body Image | Psychosocial Impairment | Survivorship | Mental Health IssueUnited States
-
Istanbul Arel UniversityIstanbul UniversityCompletedBody Image Disturbance | Eating DisordersTurkey
-
University of SheffieldCompletedBody Image Disturbance | Eating Disorder SymptomUnited Kingdom
-
Union College, New YorkUniversity at AlbanyCompletedBody Image Disturbance | Eating Disorder SymptomUnited States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingWeight Loss | Overweight and Obesity | Body Image DisturbanceUnited States
Clinical Trials on UV fluorescent ink
-
Temple UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingDiarrhea | Respiratory Viral Infection | Gastrointestinal Infection | Waterborne DiseasesUnited States
-
University of MinnesotaCompletedProteomicsUnited States
-
Emergent BioSolutionsQuintiles, Inc.; Unither VirologyCompleted
-
Nuwacell Biotechnologies Co., Ltd.Not yet recruiting
-
The Ottawa HospitalWithdrawnBreast Cancer | Axillary LymphadenitisCanada
-
Dana-Farber Cancer InstituteTerminated
-
West Virginia UniversitySuspendedCutaneous Tumors | Skin CancersUnited States
-
University of Colorado, DenverCompletedNevi and MelanomasUnited States
-
University of MichiganArchimedes Innovations, PbcActive, not recruitingHealthy VolunteersUnited States
-
Erasmus Medical CenterNot yet recruitingSolid Tumor, AdultNetherlands